Bristol BuSpar Metabolite Patent Issued One Day Before Watson Generic
Executive Summary
Bristol-Myers Squibb's last-minute patent listing for BuSpar is based on the discovery of an anxiolytic action for a buspirone metabolite.
You may also be interested in...
Mylan Buspirone Launch Awaits Bristol Appeal Of BuSpar Patent Order
Bristol-Myers Squibb appears to have at least two more chances to block a generic version of BuSpar from coming to market following a March 13 preliminary injunction imposed by Judge Ricardo Urbina in Washington, D.C. federal court.
Mylan Buspirone Launch Awaits Bristol Appeal Of BuSpar Patent Order
Bristol-Myers Squibb appears to have at least two more chances to block a generic version of BuSpar from coming to market following a March 13 preliminary injunction imposed by Judge Ricardo Urbina in Washington, D.C. federal court.
Bristol Glucophage XR Gets 35% Of New Rxs From Metformin Switches
Bristol-Myers Squibb's Glucophage XR extended-release metformin for type 2 diabetes is getting 35% of its new prescriptions from patients switching off the company's immediate-release Glucophage, Bristol President-Worldwide Medicines Group Richard Lane told a Jan. 24 conference call.